HRP20231438T1 - Formulacije oksitocina koje sadrže magnezij i načini uporabe - Google Patents
Formulacije oksitocina koje sadrže magnezij i načini uporabe Download PDFInfo
- Publication number
- HRP20231438T1 HRP20231438T1 HRP20231438TT HRP20231438T HRP20231438T1 HR P20231438 T1 HRP20231438 T1 HR P20231438T1 HR P20231438T T HRP20231438T T HR P20231438TT HR P20231438 T HRP20231438 T HR P20231438T HR P20231438 T1 HRP20231438 T1 HR P20231438T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- oxytocin peptide
- magnesium
- magnesium salt
- oxytocin
- Prior art date
Links
- 101800000989 Oxytocin Proteins 0.000 title claims 24
- 239000000203 mixture Substances 0.000 title claims 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims 6
- 229910052749 magnesium Inorganic materials 0.000 title claims 6
- 239000011777 magnesium Substances 0.000 title claims 6
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 17
- 159000000003 magnesium salts Chemical class 0.000 claims 13
- 230000036407 pain Effects 0.000 claims 13
- 229940091250 magnesium supplement Drugs 0.000 claims 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 101500028587 Homo sapiens Oxytocin Proteins 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000007613 Shoulder Pain Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 210000004889 cervical nerve Anatomy 0.000 claims 2
- 230000001667 episodic effect Effects 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 229960005336 magnesium citrate Drugs 0.000 claims 2
- 235000002538 magnesium citrate Nutrition 0.000 claims 2
- 239000004337 magnesium citrate Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 210000003901 trigeminal nerve Anatomy 0.000 claims 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 2
- 210000001364 upper extremity Anatomy 0.000 claims 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910001425 magnesium ion Inorganic materials 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562100862P | 2015-01-07 | 2015-01-07 | |
| EP16735422.4A EP3242676B1 (en) | 2015-01-07 | 2016-01-07 | Magnesium-containing oxytocin formulations and methods of use |
| PCT/US2016/012512 WO2016112205A1 (en) | 2015-01-07 | 2016-01-07 | Magnesium-containing oxytocin formulations and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231438T1 true HRP20231438T1 (hr) | 2024-06-07 |
Family
ID=56285908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231438TT HRP20231438T1 (hr) | 2015-01-07 | 2016-01-07 | Formulacije oksitocina koje sadrže magnezij i načini uporabe |
Country Status (24)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3242676T3 (pl) * | 2015-01-07 | 2024-07-15 | Tonix Pharma Limited | Preparaty oksytocyny zawierające magnez i sposoby ich stosowania |
| HRP20250215T1 (hr) | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| CN111278425B (zh) * | 2017-09-11 | 2024-06-11 | 耶路撒冷希伯来大学伊萨姆研究开发有限公司 | 用于向脑部经鼻给药药物和用于全身作用的组合物和方法 |
| EP3759121A1 (en) * | 2018-03-01 | 2021-01-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
| US20230414492A1 (en) * | 2019-04-02 | 2023-12-28 | Nose To Brain Therapeutics Llc | Intranasal delivery of cannabidiol to treat central nervous system disorders |
| US11241477B2 (en) | 2019-08-29 | 2022-02-08 | New York University | Oxytocin compositions for treatment of tinnitus |
| WO2022200568A1 (en) | 2021-03-26 | 2022-09-29 | Ot4B | Treatment of dysphagia |
| GB2607333A (en) * | 2021-06-03 | 2022-12-07 | Horopito Ltd | Pain relief composition |
| WO2023091469A1 (en) * | 2021-11-17 | 2023-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting periosteal tissue for delivery of therapeutics |
| CN115569186A (zh) * | 2022-08-02 | 2023-01-06 | 北京大学第三医院（北京大学第三临床医学院） | 一种包含催产素的用于治疗干眼症的药物组合物 |
| US20250255930A1 (en) * | 2024-02-08 | 2025-08-14 | Maskbegone Llc | Methods of treatment of tinnitus using derivatives of oxytocin |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE431291C (de) | 1925-03-29 | 1926-07-08 | Contessa Nettel A G | Wechselkassette mit herausziehbarer Wechsellade |
| US1936364A (en) | 1930-08-22 | 1933-11-21 | Pfizer Charles & Co | Citrate solutions |
| US2260004A (en) | 1939-11-03 | 1941-10-21 | Pfizer Charles & Co | Stable soluble magnesium acid citrate |
| US2938891A (en) | 1956-03-30 | 1960-05-31 | Roussel Uclaf | Method of making oxytocin and intermediates thereof |
| US3076797A (en) | 1957-07-22 | 1963-02-05 | Roussel Uclaf | Process of producing oxytocin and intermediates obtained thereby |
| US4213968A (en) | 1978-06-05 | 1980-07-22 | Coy David Howard | Enkephalin derivatives |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4486441A (en) | 1982-12-03 | 1984-12-04 | Merrell Toraude Et Compagnie | Pseudotropyl halogeno-benzoates and their use in migraine treatment |
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| ATE78158T1 (de) | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
| NZ226557A (en) | 1987-10-15 | 1990-07-26 | Syntex Inc | Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation |
| US4885287A (en) | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
| AU6909091A (en) | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US6407061B1 (en) | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
| US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| GB9203769D0 (en) | 1992-02-21 | 1992-04-08 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| DE4312913A1 (de) | 1992-10-23 | 1994-10-13 | Knauf Siegfried | Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| IL109403A0 (en) | 1993-04-22 | 1994-07-31 | Emisphere Tech Inc | Oral drug delivery compositions and methods |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5837809A (en) | 1995-08-11 | 1998-11-17 | Oregon Health Sciences University | Mammalian opioid receptor ligand and uses |
| US6054462A (en) | 1994-04-13 | 2000-04-25 | Janssen Pharmaceutica, N.V. | Intranasal antimigraine compositions |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| CA2209016A1 (en) | 1994-12-28 | 1996-07-04 | Teikoku Hormone Mfg. Co., Ltd. | Pharmaceutics for mucosal administration |
| US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| CN1155368C (zh) * | 1996-02-27 | 2004-06-30 | 帝人株式会社 | 鼻腔给药的粉剂组合物 |
| DE19627228A1 (de) | 1996-07-05 | 1998-01-08 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| US5914129A (en) * | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US5798266A (en) | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
| US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| SE9701162D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
| SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
| AU8333998A (en) | 1997-07-15 | 1999-02-10 | Novo Nordisk A/S | New use of nociceptin |
| US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| US20030185761A1 (en) | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US6143278A (en) | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
| US6090368A (en) | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
| AU757658B2 (en) | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6068999A (en) * | 1998-06-25 | 2000-05-30 | Hendrix; Curt | Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| WO2000033813A1 (en) | 1998-12-09 | 2000-06-15 | Chiron Corporation | Administration of neurotrophic agents to the central nervous system |
| US7273618B2 (en) | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| EP1135105B1 (en) | 1998-12-09 | 2005-03-02 | Chiron Corporation | Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder |
| US6139861A (en) | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
| TR200103613T2 (tr) | 1999-06-16 | 2004-08-23 | Nastech Pharmaceutical Co., Inc. | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. |
| JP2001002589A (ja) | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
| JP2001089359A (ja) | 1999-09-24 | 2001-04-03 | Toko Yakuhin Kogyo Kk | 鎮痛成分の点鼻用ゲルまたはゾル製剤 |
| WO2001026642A2 (en) * | 1999-10-08 | 2001-04-19 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
| AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
| WO2001041782A2 (en) | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| ATE290856T1 (de) | 1999-12-16 | 2005-04-15 | Dermatrends Inc | Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit |
| US6413499B1 (en) | 2000-01-06 | 2002-07-02 | Bryan M. Clay | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic |
| JP2001233787A (ja) | 2000-02-04 | 2001-08-28 | Patents Exploitation Co Bv | 小・中サイズのペプチド含有薬学的組成物 |
| EP1121935B1 (en) | 2000-02-04 | 2008-08-13 | Patents Exploitation Company B.V. | Pharmaceutical composition containing a small or medium size peptide |
| AU4876701A (en) | 2000-04-14 | 2001-10-30 | Nippon Shinyaku Co. Ltd. | Peptide derivatives and medicinal compositions |
| KR20030060771A (ko) | 2000-04-28 | 2003-07-16 | 메모리얼 슬로안-케터링 캔서 센터 | 국소용 마취제/아편양약물 제제 및 이들의 용도 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| AU2001262992A1 (en) | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
| IL137820A (en) | 2000-08-10 | 2009-06-15 | S I S Shulov Inst For Science | Pharmaceutical composition for topical administration comprising an analgesic peptide |
| US20020082215A1 (en) | 2000-10-13 | 2002-06-27 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
| US20070112052A9 (en) | 2001-01-05 | 2007-05-17 | Larry Caldwell | Methods and compositions for treating headache pain with topical NSAID compositions |
| JP2005500258A (ja) | 2001-03-23 | 2005-01-06 | アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ | Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。 |
| US20020169102A1 (en) | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
| WO2002086105A1 (en) | 2001-04-20 | 2002-10-31 | Chiron Corporation | Delivery of polynucleotide agents to the central nervous sysstem |
| US7820688B2 (en) | 2001-04-27 | 2010-10-26 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| SE0102184D0 (sv) | 2001-06-19 | 2001-06-19 | Uvnaes Moberg Kerstin | New subject-matter |
| IL161446A0 (en) | 2001-11-26 | 2004-09-27 | Daiichi Suntory Pharma Co Ltd | Medicinal compositions for nasal absorption |
| US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| US20070004743A1 (en) | 2002-02-25 | 2007-01-04 | Xiao Linda L | Intranasal administration of mc4-r agonists |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
| US20040105889A1 (en) | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| JP2005523326A (ja) | 2002-04-22 | 2005-08-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | プロテインキナーゼｃのペプチドインヒビター |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| PT1499888E (pt) | 2002-04-29 | 2010-10-14 | Euro Celtique Sa | Péptidos conformacionalmente constrangidos que se ligam ao receptor orl-1 |
| WO2003093816A2 (en) | 2002-05-02 | 2003-11-13 | Bayer Healtchare Ag | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| EP2283864A1 (en) | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| AU2003273247A1 (en) | 2002-08-30 | 2004-03-19 | Board Of Regents, The University Of Texas System | Non-invasive methods to identify agents for treating pain |
| ITMI20022022A1 (it) | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
| ATE477811T1 (de) | 2002-10-03 | 2010-09-15 | Neuropharmacology Services Llc | Oxytocin zur behandlung von autismus und asperger-syndrom |
| WO2004062563A2 (en) | 2003-01-16 | 2004-07-29 | Université de Lausanne | Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders |
| WO2004073646A2 (en) | 2003-02-19 | 2004-09-02 | University Of Rochester | Treatment of pain through expression of opioid receptors |
| EP1468690B1 (en) | 2003-03-27 | 2008-10-08 | Pantarhei Bioscience B.V. | Use of estrogens for the treatment of infertility in male mammals |
| CA2520655A1 (en) | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
| GB0319119D0 (en) | 2003-08-14 | 2003-09-17 | Optinose As | Delivery devices |
| US20050153885A1 (en) | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| WO2005060947A2 (en) | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| WO2005115370A2 (en) | 2004-04-23 | 2005-12-08 | The Regents Of The University Of California | Compounds and methods for treating non-inflammatory pain using pparalpha agonists |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| PL1877073T3 (pl) | 2004-12-01 | 2014-03-31 | The Sec Dep For Health | Niecytotoksyczne koniugaty białkowe |
| MX2007010244A (es) | 2005-02-23 | 2008-03-10 | Johnson & Johnson | Administracion intranasal de agentes activos al sistema nervioso central. |
| WO2006099288A2 (en) | 2005-03-11 | 2006-09-21 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
| US20060252685A1 (en) | 2005-05-04 | 2006-11-09 | Gould Jeffrey D | Treatment for sleep apnea |
| JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| US8142803B2 (en) | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| EP2152240A4 (en) | 2007-06-08 | 2012-05-09 | Healthpartners Res Foundation | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM |
| JP2009073744A (ja) * | 2007-09-19 | 2009-04-09 | Saitama Medical Univ | 片頭痛の予防治療剤 |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| JP5467785B2 (ja) | 2009-03-25 | 2014-04-09 | 大塚製薬株式会社 | 抗鳥インフルエンザウイルス抗体の産生促進剤 |
| DK2459183T3 (en) * | 2009-07-27 | 2016-01-18 | Nocicepta Llc | Methods for the treatment of pain |
| JP5491119B2 (ja) | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| WO2011120071A1 (en) | 2010-04-01 | 2011-10-06 | The University Of Queensland | Oxytocin peptide analogues |
| EP2576598A4 (en) | 2010-06-07 | 2014-08-13 | Univ Queensland | NOZIZEPTIN mimetics |
| WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
| JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| US20120252894A1 (en) * | 2011-04-01 | 2012-10-04 | Giniatullin Rashid | Compounds for alleviating pain and stress in fetus and newborn |
| SE536091C2 (sv) | 2011-04-14 | 2013-04-30 | Pep Tonic Medical Ab | Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter |
| WO2014057092A1 (en) * | 2012-10-12 | 2014-04-17 | Pep-Tonic Medical Ab | Novel use of a composition comprising oxytocin |
| US20140147519A1 (en) * | 2012-11-26 | 2014-05-29 | Larry A. MCPHAIL | Migraine Treatment |
| PL3242676T3 (pl) * | 2015-01-07 | 2024-07-15 | Tonix Pharma Limited | Preparaty oksytocyny zawierające magnez i sposoby ich stosowania |
-
2016
- 2016-01-07 PL PL16735422.4T patent/PL3242676T3/pl unknown
- 2016-01-07 EP EP23201255.9A patent/EP4331670A3/en active Pending
- 2016-01-07 EP EP16735422.4A patent/EP3242676B1/en active Active
- 2016-01-07 SM SM20240020T patent/SMT202400020T1/it unknown
- 2016-01-07 RU RU2017127734A patent/RU2017127734A/ru not_active Application Discontinuation
- 2016-01-07 US US14/990,529 patent/US9629894B2/en active Active
- 2016-01-07 US US15/541,991 patent/US11389473B2/en active Active
- 2016-01-07 MX MX2017008913A patent/MX388286B/es unknown
- 2016-01-07 JP JP2017535877A patent/JP7030517B2/ja active Active
- 2016-01-07 WO PCT/US2016/012512 patent/WO2016112205A1/en not_active Ceased
- 2016-01-07 LT LTEPPCT/US2016/012512T patent/LT3242676T/lt unknown
- 2016-01-07 SG SG11201705591PA patent/SG11201705591PA/en unknown
- 2016-01-07 KR KR1020177021998A patent/KR102677904B1/ko active Active
- 2016-01-07 CN CN201680013809.5A patent/CN107847552B/zh active Active
- 2016-01-07 CA CA2972975A patent/CA2972975A1/en active Pending
- 2016-01-07 FI FIEP16735422.4T patent/FI3242676T3/fi active
- 2016-01-07 RS RS20240018A patent/RS65034B1/sr unknown
- 2016-01-07 PT PT167354224T patent/PT3242676T/pt unknown
- 2016-01-07 HU HUE16735422A patent/HUE065385T2/hu unknown
- 2016-01-07 AU AU2016205225A patent/AU2016205225A1/en not_active Abandoned
- 2016-01-07 DK DK16735422.4T patent/DK3242676T3/da active
- 2016-01-07 ES ES16735422T patent/ES2963707T3/es active Active
- 2016-01-07 SI SI201631762T patent/SI3242676T1/sl unknown
- 2016-01-07 HR HRP20231438TT patent/HRP20231438T1/hr unknown
-
2017
- 2017-07-06 IL IL253347A patent/IL253347B/en unknown
- 2017-07-31 ZA ZA2017/05176A patent/ZA201705176B/en unknown
-
2020
- 2020-12-09 AU AU2020286221A patent/AU2020286221B2/en active Active
-
2021
- 2021-11-02 JP JP2021179295A patent/JP7455402B2/ja active Active
-
2024
- 2024-03-06 JP JP2024033983A patent/JP7756953B2/ja active Active
- 2024-05-23 AU AU2024203428A patent/AU2024203428A1/en active Pending
-
2025
- 2025-10-01 JP JP2025165798A patent/JP2025185044A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3242676T3 (fi) | Magnesiumipitoisia oksitosiiniformulaatioita ja käyttömenetelmiä | |
| JP2018502856A5 (cg-RX-API-DMAC10.html) | ||
| PH12017500479A1 (en) | Liquid inhalation formulation comprising prl554 | |
| HRP20211198T1 (hr) | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| HRP20191777T1 (hr) | Vodena farmaceutska formulacija tapentadola za oralnu primjenu | |
| HRP20221367T1 (hr) | Brzodjelujući inzulinski pripravci | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| KR20150011807A (ko) | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 | |
| PH12019501016A1 (en) | Treatment of cns diseases with sgc stimulators | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| JP2022003099A5 (cg-RX-API-DMAC10.html) | ||
| JP2011520894A5 (cg-RX-API-DMAC10.html) | ||
| ATE507818T1 (de) | Orale verabreichung eines calcitonins | |
| FI3848028T3 (fi) | Okulaaristen sairauksien hoitomenetelmiä | |
| HRP20181079T1 (hr) | Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja | |
| PH12018500817B1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| HRP20201726T1 (hr) | Liječenje valunga i gubitka kostiju izazvanih terapijom uskraćivanja androgena pomoću cis-klomifena | |
| HRP20191243T1 (hr) | Topikalni antifugalni pripravak za liječenje onihomikoze | |
| RU2014130894A (ru) | Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе | |
| NZ771693B2 (en) | Magnesium-containing oxytocin formulations and methods of use | |
| NZ734097B2 (en) | Magnesium-containing oxytocin formulations and methods of use | |
| HRP20250215T1 (hr) | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe | |
| WO2008098122A3 (en) | Method for treating allergic rhinitis without adverse effects | |
| MX2017004633A (es) | Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas. |